JP2019516392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516392A5 JP2019516392A5 JP2018567013A JP2018567013A JP2019516392A5 JP 2019516392 A5 JP2019516392 A5 JP 2019516392A5 JP 2018567013 A JP2018567013 A JP 2018567013A JP 2018567013 A JP2018567013 A JP 2018567013A JP 2019516392 A5 JP2019516392 A5 JP 2019516392A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- constant domain
- ilt7
- item
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000984199 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 4 Proteins 0.000 claims description 44
- 102100025555 Leukocyte immunoglobulin-like receptor subfamily A member 4 Human genes 0.000 claims description 44
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 description 18
- 108091033319 polynucleotide Proteins 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021186637A JP7354212B2 (ja) | 2016-03-10 | 2021-11-16 | Ｉｌｔ７結合分子及びその使用方法 |
| JP2023151943A JP7700190B2 (ja) | 2016-03-10 | 2023-09-20 | Ｉｌｔ７結合分子及びその使用方法 |
| JP2025101902A JP2025134836A (ja) | 2016-03-10 | 2025-06-18 | Ｉｌｔ７結合分子及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306125P | 2016-03-10 | 2016-03-10 | |
| US62/306,125 | 2016-03-10 | ||
| PCT/US2017/021616 WO2017156298A1 (en) | 2016-03-10 | 2017-03-09 | Ilt7 binding molecules and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021186637A Division JP7354212B2 (ja) | 2016-03-10 | 2021-11-16 | Ｉｌｔ７結合分子及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516392A JP2019516392A (ja) | 2019-06-20 |
| JP2019516392A5 true JP2019516392A5 (enExample) | 2020-04-16 |
| JP6979976B2 JP6979976B2 (ja) | 2021-12-15 |
Family
ID=59790876
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567013A Active JP6979976B2 (ja) | 2016-03-10 | 2017-03-09 | Ｉｌｔ７結合分子及びその使用方法 |
| JP2021186637A Active JP7354212B2 (ja) | 2016-03-10 | 2021-11-16 | Ｉｌｔ７結合分子及びその使用方法 |
| JP2023151943A Active JP7700190B2 (ja) | 2016-03-10 | 2023-09-20 | Ｉｌｔ７結合分子及びその使用方法 |
| JP2025101902A Pending JP2025134836A (ja) | 2016-03-10 | 2025-06-18 | Ｉｌｔ７結合分子及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021186637A Active JP7354212B2 (ja) | 2016-03-10 | 2021-11-16 | Ｉｌｔ７結合分子及びその使用方法 |
| JP2023151943A Active JP7700190B2 (ja) | 2016-03-10 | 2023-09-20 | Ｉｌｔ７結合分子及びその使用方法 |
| JP2025101902A Pending JP2025134836A (ja) | 2016-03-10 | 2025-06-18 | Ｉｌｔ７結合分子及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11072652B2 (enExample) |
| EP (1) | EP3426298A4 (enExample) |
| JP (4) | JP6979976B2 (enExample) |
| KR (5) | KR102802736B1 (enExample) |
| CN (2) | CN114874322A (enExample) |
| AR (2) | AR109450A1 (enExample) |
| AU (2) | AU2017231833B2 (enExample) |
| BR (1) | BR112018067951A2 (enExample) |
| CA (1) | CA3017197A1 (enExample) |
| IL (2) | IL321334A (enExample) |
| MX (2) | MX2018010771A (enExample) |
| NZ (2) | NZ785821A (enExample) |
| RU (1) | RU2756109C2 (enExample) |
| SG (2) | SG10202008769SA (enExample) |
| TW (1) | TWI755380B (enExample) |
| UA (1) | UA127731C2 (enExample) |
| WO (1) | WO2017156298A1 (enExample) |
| ZA (1) | ZA201806597B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102802736B1 (ko) | 2016-03-10 | 2025-05-02 | 비엘라 바이오, 인크. | Ilt7 결합 분자 및 이의 사용 방법 |
| CA3047833A1 (en) * | 2016-12-22 | 2018-06-28 | Icahn School Of Medicine At Mount Sinai | Anti-lilrb3 antibodies and methods of use thereof |
| CN114008076B (zh) * | 2019-04-19 | 2025-08-15 | 艾洛基治疗公司 | 针对4g7衍生的嵌合抗原受体的抗体 |
| AU2020395232A1 (en) * | 2019-12-06 | 2022-07-14 | Viela Bio, Inc. | Methods of treatment using ILT7 binding proteins |
| JP2023507369A (ja) * | 2019-12-20 | 2023-02-22 | メディミューン，エルエルシー | グリピカン３を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法 |
| WO2021203013A2 (en) * | 2020-04-03 | 2021-10-07 | Viela Bio, Inc. | Methods of treating immune mediated pulmonary injury |
| CA3217278A1 (en) | 2021-05-04 | 2022-11-10 | William Rees | Methods of treatment of autoimmune disorders using ilt7 binding proteins |
| CN119630703A (zh) | 2022-07-27 | 2025-03-14 | 维埃拉生物股份有限公司 | 包含免疫球蛋白样转录物7（ilt7）结合蛋白的配制剂 |
| AU2023393624A1 (en) | 2022-12-12 | 2025-05-15 | Viela Bio, Inc. | Anti-ilt7 binding agents for the treatment and prevention of myositis |
| KR20250160358A (ko) * | 2023-03-16 | 2025-11-12 | 인매진 피티이. 엘티디. | Ilt7-표적화 항체 및 그의 용도 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2096948A (en) | 1935-12-20 | 1937-10-26 | Anchor Steel & Conveyor Co | Conveyer system |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| DE4440354A1 (de) | 1994-11-11 | 1996-05-15 | Hoechst Schering Agrevo Gmbh | Kombinationen aus Phenylsulfonylharnstoff-Herbiziden und Safenern |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US7264963B1 (en) | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2001002588A2 (en) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| CA2399148A1 (en) | 2000-02-10 | 2001-08-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| US6897067B2 (en) | 2000-11-03 | 2005-05-24 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
| AU2001297872B2 (en) | 2000-11-17 | 2006-11-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| WO2003012061A2 (en) * | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003081376A2 (en) | 2002-03-20 | 2003-10-02 | Catalina Marketing International Inc. | Targeted incentives based upon predicted behavior |
| EP2316922B1 (en) | 2002-05-24 | 2013-05-22 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
| AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| US20070025992A1 (en) * | 2003-07-18 | 2007-02-01 | Mochida Pharmaceutical Co., Ltd | Monoclonal antibody against platelet membrane glycoprotein VI |
| US9208495B2 (en) | 2003-10-06 | 2015-12-08 | Yellowpages.Com Llc | Methods and apparatuses for advertisement presentation |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CA2597265C (en) * | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| AU2012244391B2 (en) | 2005-12-20 | 2014-09-11 | Sbi Biotech Co., Ltd. | Anti-ILT7 antibody |
| KR101624587B1 (ko) * | 2005-12-20 | 2016-05-26 | 에스비아이 바이오테크 가부시키가이샤 | 항-ｉｌｔ7 항체 |
| MX2008012754A (es) * | 2006-04-07 | 2009-04-27 | Us Gov Health & Human Serv | Composiciones de anticuerpos y metodos para tratamiento de enfermedad neoplastica. |
| CA2652599C (en) | 2006-05-03 | 2019-09-24 | Ross Kedl | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
| US7781306B2 (en) | 2007-06-20 | 2010-08-24 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor substrate and method for manufacturing the same |
| US20110311558A1 (en) | 2008-12-01 | 2011-12-22 | The Board Of Regents Of The University Of Texas System | Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases |
| ES2613055T3 (es) | 2009-09-03 | 2017-05-22 | Medimmune, Llc | Diagnóstico de interferón de tipo 1 |
| US20120316071A1 (en) | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
| CA2834203A1 (en) | 2011-04-26 | 2012-11-01 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| EP3421591B1 (en) | 2011-04-28 | 2023-09-27 | The Board of Trustees of the Leland Stanford Junior University | Identification of polynucleotides associated with a sample |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| DK2809683T3 (en) * | 2012-01-31 | 2018-12-10 | Sbi Biotech Co Ltd | ANTI-phospholipase D 4 ANTIBODY |
| US8605807B1 (en) | 2012-05-22 | 2013-12-10 | Nigel Iain Stuart Macrae | Communicating distinct data over a single frequency using multiple linear polarized signals |
| CA3240136A1 (en) * | 2012-11-08 | 2014-05-15 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| US9114438B2 (en) | 2013-05-21 | 2015-08-25 | Applied Materials, Inc. | Copper residue chamber clean |
| AU2015308625A1 (en) | 2014-08-29 | 2017-04-20 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind OprF and Oprl |
| KR102802736B1 (ko) | 2016-03-10 | 2025-05-02 | 비엘라 바이오, 인크. | Ilt7 결합 분자 및 이의 사용 방법 |
| AU2020395232A1 (en) | 2019-12-06 | 2022-07-14 | Viela Bio, Inc. | Methods of treatment using ILT7 binding proteins |
| CA3217278A1 (en) | 2021-05-04 | 2022-11-10 | William Rees | Methods of treatment of autoimmune disorders using ilt7 binding proteins |
-
2017
- 2017-03-09 KR KR1020247003436A patent/KR102802736B1/ko active Active
- 2017-03-09 CN CN202210535107.0A patent/CN114874322A/zh active Pending
- 2017-03-09 KR KR1020187028675A patent/KR102439395B1/ko active Active
- 2017-03-09 UA UAA201810089A patent/UA127731C2/uk unknown
- 2017-03-09 NZ NZ785821A patent/NZ785821A/en unknown
- 2017-03-09 NZ NZ746609A patent/NZ746609A/en unknown
- 2017-03-09 BR BR112018067951-8A patent/BR112018067951A2/pt active Search and Examination
- 2017-03-09 CN CN201780029035.XA patent/CN109414499B/zh active Active
- 2017-03-09 US US16/083,825 patent/US11072652B2/en active Active
- 2017-03-09 RU RU2018135550A patent/RU2756109C2/ru active
- 2017-03-09 EP EP17764118.0A patent/EP3426298A4/en active Pending
- 2017-03-09 SG SG10202008769SA patent/SG10202008769SA/en unknown
- 2017-03-09 WO PCT/US2017/021616 patent/WO2017156298A1/en not_active Ceased
- 2017-03-09 KR KR1020257011739A patent/KR20250051802A/ko active Pending
- 2017-03-09 SG SG11201807523PA patent/SG11201807523PA/en unknown
- 2017-03-09 CA CA3017197A patent/CA3017197A1/en active Pending
- 2017-03-09 MX MX2018010771A patent/MX2018010771A/es unknown
- 2017-03-09 KR KR1020227029604A patent/KR102603010B1/ko active Active
- 2017-03-09 IL IL321334A patent/IL321334A/en unknown
- 2017-03-09 JP JP2018567013A patent/JP6979976B2/ja active Active
- 2017-03-09 KR KR1020237034385A patent/KR102632796B1/ko active Active
- 2017-03-09 AU AU2017231833A patent/AU2017231833B2/en active Active
- 2017-03-10 TW TW106107877A patent/TWI755380B/zh active
- 2017-03-29 AR ARP170100775A patent/AR109450A1/es unknown
-
2018
- 2018-09-06 IL IL261653A patent/IL261653B2/en unknown
- 2018-09-06 MX MX2023010076A patent/MX2023010076A/es unknown
- 2018-10-04 ZA ZA2018/06597A patent/ZA201806597B/en unknown
-
2021
- 2021-05-28 AR ARP210101444A patent/AR122196A2/es unknown
- 2021-06-17 US US17/350,271 patent/US11673950B2/en active Active
- 2021-11-16 JP JP2021186637A patent/JP7354212B2/ja active Active
-
2023
- 2023-04-21 US US18/305,165 patent/US20230250167A1/en active Pending
- 2023-09-20 JP JP2023151943A patent/JP7700190B2/ja active Active
-
2024
- 2024-06-03 AU AU2024203701A patent/AU2024203701A1/en active Pending
-
2025
- 2025-06-18 JP JP2025101902A patent/JP2025134836A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516392A5 (enExample) | ||
| CA2987118C (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| KR102003754B1 (ko) | Pd-l1 항체와 이를 이용한 치료 및 진단 | |
| CN112135626A (zh) | 抗tigit抗体及其用途 | |
| CN115003333A (zh) | Pvrig结合蛋白及其医药用途 | |
| JP2020508655A5 (enExample) | ||
| JP2014509861A5 (enExample) | ||
| HRP20131215T1 (hr) | Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope | |
| CN113874400A (zh) | 抗Vβ17/抗CD123双特异性抗体 | |
| CN114901697A (zh) | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 | |
| JP2012526558A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| RU2020130795A (ru) | Нейтрализующие антитела к env вич-1 и их применение | |
| RU2018135550A (ru) | Связывающие ilt7 молекулы и способы их применения | |
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| JP2019528046A5 (enExample) | ||
| RU2019103991A (ru) | Анти-il-22r-антитела | |
| RU2020128108A (ru) | Антитело против cd25 для опухоль-специфической клеточной деплеции | |
| JPWO2021213475A5 (enExample) | ||
| AU2021231712A1 (en) | Anti-CD19 antibodies and methods of using and making thereof | |
| JPWO2022218380A5 (enExample) | ||
| JPWO2023078382A5 (enExample) | ||
| RU2844744C1 (ru) | Антитела против фактора стволовых клеток и способы их применения | |
| WO2025024780A1 (en) | Antibodies that bind gamma-delta t cell receptors for the treatment of cancer |